Munich / Jena, June 11, 2012 – Wacker Biotech and XL-protein have successfully completed a feasibility study on the production of PASylated therapeutic proteins using WACKER’s ESETEC® E. coli secretion technology. In the study, WACKER technology was used to investigate the production of a PASylated human growth hormone as model protein. WACKER developed a cell […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362012-06-11 11:51:372016-06-16 12:00:25XL-protein and Wacker demonstrate high-yield production of PASylated biopharmaceuticals using ESETEC®
FREISING, GERMANY, September 23, 2011 – XL-protein GmbH, a German biotech company specialised in the development of biopharmaceuticals with extended plasma half-life, announced today preclinical in vitro and in vivo data for its xl020 PAS-hGH program. The xl020 data demonstrate XL-protein’s ability to furnish an approved biological drug with improved in vivo stability and plasma […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362011-09-23 12:02:442016-06-16 12:05:35XL-protein announces in vitro and in vivo data for its PASylated hGH
FREISING, GERMANY, MARCH 17th, 2011 – XL-protein GmbH, a German biotech company that specialises in the development of biopharmaceuticals with extended plasma half-life, today announced that the European Patent Office granted a core patent (EP2173890) for XL-protein’s PASylation® technology. Beside the granted PASylation® EP patent, several other corresponding national patent applications are currently processed worldwide. […]
XL-protein and Wacker demonstrate high-yield production of PASylated biopharmaceuticals using ESETEC®
Munich / Jena, June 11, 2012 – Wacker Biotech and XL-protein have successfully completed a feasibility study on the production of PASylated therapeutic proteins using WACKER’s ESETEC® E. coli secretion technology. In the study, WACKER technology was used to investigate the production of a PASylated human growth hormone as model protein. WACKER developed a cell […]
XL-protein announces in vitro and in vivo data for its PASylated hGH
FREISING, GERMANY, September 23, 2011 – XL-protein GmbH, a German biotech company specialised in the development of biopharmaceuticals with extended plasma half-life, announced today preclinical in vitro and in vivo data for its xl020 PAS-hGH program. The xl020 data demonstrate XL-protein’s ability to furnish an approved biological drug with improved in vivo stability and plasma […]
European patent granted for XL-protein’s PASylation® technology
FREISING, GERMANY, MARCH 17th, 2011 – XL-protein GmbH, a German biotech company that specialises in the development of biopharmaceuticals with extended plasma half-life, today announced that the European Patent Office granted a core patent (EP2173890) for XL-protein’s PASylation® technology. Beside the granted PASylation® EP patent, several other corresponding national patent applications are currently processed worldwide. […]